Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 6/20 | 0.63 |
| ▸ | NISCH | Q9Y2I1 | 4/20 | 0.56 |
| ▸ | HTR1D | P28221 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.51 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.51 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.51 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20198570 | 0.84 | PRMT1 (0.68) | PRMT1NISCHPRMT3EHMT2PRMT6 | |
| SCHEMBL8229714 | 0.81 | PRMT1 (0.71) | PRMT1NISCHPRMT3EHMT2PRMT6 | |
| SCHEMBL8238119 | 0.80 | PRMT1 (0.69) | PRMT1NISCHPRMT3EHMT2PRMT6 | |
| SCHEMBL362453 | 0.78 | PRMT1 (0.68) | PRMT1NISCHPRMT3EHMT2PRMT6 | |
| SCHEMBL10125964 | 0.78 | PRMT1 (0.63) | PRMT1NISCHPRMT3EHMT2PRMT6 | |
| SCHEMBL8235649 | 0.77 | PRMT1 (1.00) | PRMT1NISCHPRMT3EHMT2PRMT6 | |
| Hydrochloric Acid SCHEMBL3383477 | 0.77 | PRMT1 (0.66) | PRMT1NISCHPRMT3EHMT2PRMT6 | |
| SCHEMBL14535010 | 0.77 | PRMT1 (0.70) | PRMT1NISCHPRMT3EHMT2PRMT6 | |
| SCHEMBL14865430 | 0.76 | NISCH (0.79) | PRMT1NISCH | |
| SCHEMBL13135587 | 0.75 | NISCH (0.86) | PRMT1NISCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207209-B2 | Methods of inhibiting viral infection | FUNCTIONAL GENETICS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20120035198-A1 | Antiviral Compounds and Methods of Using Thereof | AMAN MOHAMMAD JAVAD (US) | 2012-02-09 | — | — | US | disclosed |
| US-7999001-B2 | Antiviral compounds and methods of using thereof | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2011-08-16 | — | — | US | disclosed |
| US-20110086877-A1 | Small Molecule Inhibitors of Botulinum Neurotoxins | BAVARI SINA | 2011-04-14 | — | — | US | disclosed |
| US-7825154-B2 | Small molecule inhibitors of botulinum neurotoxins | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2010-11-02 | — | — | US | disclosed |
| US-20090170890-A1 | METHOHDS OF INHIBITING VIRAL INFECTION | FUNCTIONAL GENETICS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090012107-A1 | Antiviral Compounds and Methods of Using Thereof | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2009-01-08 | — | — | US | disclosed |
| US-20070112048-A1 | Broad Spectrum Antibacterial Compounds | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2007-05-17 | — | — | US | disclosed |
| US-20070112049-A1 | nonpeptidic inhibitors of Botulinum neurotoxin A metalloprotease activity, such as 2-[4-(4-carbamimidoylphenoxy)phenyl]-1H-indole-5-carboximidamide, used for treating, inhibiting or preventing intoxication caused by bacteria | ARMY, UNITED STATES | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012107-A1 | Antiviral Compounds and Methods of Using Thereof | ZC3HAV1, MAVS, ZC3HAV1L | PRMT1 1610/4885NISCH 91/4885HTR1D 4757/4885 |
| US-20070112048-A1 | Broad Spectrum Antibacterial Compounds | MPO, CAT, LPO | PRMT1 2817/4885NISCH 33/4885HTR1D 4103/4885 |
| US-20120035198-A1 | Antiviral Compounds and Methods of Using Thereof | ZC3HAV1, MAVS, ZC3HAV1L | PRMT1 1610/4885NISCH 91/4885HTR1D 4757/4885 |
| US-20070112049-A1 | nonpeptidic inhibitors of Botulinum neurotoxin A metalloprotease activity, such as 2-[4-(4-carbamimidoylphenoxy)phenyl]-1H-indole-5-carboximidamide, used for treating, inhibiting or preventing intoxication caused by bacteria | ACHE, CTRL, MMP2 | PRMT1 1502/4885NISCH 181/4885HTR1D 1048/4885 |
| US-20110086877-A1 | Small Molecule Inhibitors of Botulinum Neurotoxins | ACHE, MMP2, TIMP3 | PRMT1 2768/4885NISCH 268/4885HTR1D 1867/4885 |
| US-20090170890-A1 | METHOHDS OF INHIBITING VIRAL INFECTION | CASP8, CASP1, CASP3 | PRMT1 532/4885NISCH 1324/4885HTR1D 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.